Dazodalibep Meets Phase 3 Sjogren Disease Endpoint

Company Amgen Event Type Phase 3 Clinical Readout Modality CD40 Ligand Antagonist Fusion Protein Asset Dazodalibep Target CD40 Ligand (CD40L) Disease Area Systemic Sjogren Disease Summary Amgen reported that the approximately 621-participant OASIZ 301 trial met its Week 48 primary endpoint in adults with moderate-to-severe…